Thank you for the coverage, very interesting company indeed. Can you elaborate a bit more on the competitive landscape? It seems like Pulsetto has clinical trial results (with more coming in 2025 and 2026) and has moved into defense applications, and has the endorsement of Brian Johnson (huge optionality if the "don't die" community grows). Should ECOR just acquire them outright? Or do you think it's not a threat?
What has happened to the stock price? The 2024 numbers seemed ok!
Thank you for the coverage, very interesting company indeed. Can you elaborate a bit more on the competitive landscape? It seems like Pulsetto has clinical trial results (with more coming in 2025 and 2026) and has moved into defense applications, and has the endorsement of Brian Johnson (huge optionality if the "don't die" community grows). Should ECOR just acquire them outright? Or do you think it's not a threat?
Would love to know your thoughts, also tagged you on X